Regentis Biomaterials Ltd. (NYSE American: RGNT) Builds Commercial and Regulatory Momentum as GelrinC Advances Toward Key Clinical and Regulatory Milestones
Regentis is advancing GelrinC through a pivotal stage of development, with key catalysts including U.S. clinical study enrollment, European commercialization…